With a market capitalization (market cap) of $15.46B — a measure of how much the company is worth — Ascendis Pharma A/S is the 723rd most valuable company in Healthcare as of August 18, 2026. Shares trade at $248.85, up +0.59% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Visit websiteAs of August 18, 2026, Ascendis Pharma A/S (ASND) is worth $15.46B — this is its market capitalization, the total value of all its outstanding shares.
Ascendis Pharma A/S’s market cap is $15.46B, which ranks it #723 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Ascendis Pharma A/S (ASND) shares trade at $248.85, up 0.59% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025